Cardiovascular Disease: An Introduction

Thiriet, Marc

doi:10.1007/978-3-319-89315-0_1

Cited by 35 publications

(32 citation statements)

References 170 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cardiovascular disorders, associated with many factors, involve various congenital and acquired ailments. Cardiovascular disorders include atherosclerosis with its subtypes, such as coronary, cerebral, and peripheral artery disease, along with two main complexities, myocardial infarction and ischemic stroke, heart failure, cardiac valvulopathies and arrhythmias, rheumatic heart disease, congenital heart disease, deep vein thrombosis with its specific complexities, and pulmonary embolism [80]. It comprises the main noncommunicable reason for death in Europe specifically, and also globally [80].…”

Section: Nano-phytopharmaceuticals In Cardiovascular Disordersmentioning

confidence: 99%

Precision and Advanced Nano-Phytopharmaceuticals for Therapeutic Applications

et al. 2022

View full text Add to dashboard Cite

Phytopharmaceuticals have been widely used globally since ancient times and acknowledged by healthcare professionals and patients for their superior therapeutic value and fewer side-effects compared to modern medicines. However, phytopharmaceuticals need a scientific and methodical approach to deliver their components and thereby improve patient compliance and treatment adherence. Dose reduction, improved bioavailability, receptor selective binding, and targeted delivery of phytopharmaceuticals can be likely achieved by molding them into specific nano-formulations. In recent decades, nanotechnology-based phytopharmaceuticals have emerged as potential therapeutic candidates for the treatment of various communicable and non-communicable diseases. Nanotechnology combined with phytopharmaceuticals broadens the therapeutic perspective and overcomes problems associated with plant medicine. The current review highlights the therapeutic application of various nano-phytopharmaceuticals in neurological, cardiovascular, pulmonary, and gastro-intestinal disorders. We conclude that nano-phytopharmaceuticals emerge as promising therapeutics for many pathological conditions with good compliance and higher acceptance.

show abstract

Section: Nano-phytopharmaceuticals In Cardiovascular Disordersmentioning

confidence: 99%

Precision and Advanced Nano-Phytopharmaceuticals for Therapeutic Applications

et al. 2022

View full text Add to dashboard Cite

show abstract

“…[4][5][6][7] This association is relevant because of the increase in the incidence of non-communicable disorders (diabetes, obesity, cancer, cardiovascular diseases, and neurological disorders) experienced in the last decades. [8][9][10][11] The epidemiological indicators on these processes show diabetes, cancer, and cardiovascular diseases as responsible for up to 29.1 million deaths per year. [12][13][14][15] Even more important, the incidence of these pathologies is expected to increase in the next decades and, proportionally, the costs for the health systems that nowadays account altogether for almost 5 trillion USD per year.…”

Section: Introductionmentioning

confidence: 99%

Contribution of the diverse experimental models to unravelling the biological scope of dietary (poly)phenols

et al. 2022

View full text Add to dashboard Cite

The health benefits associated with (poly)phenols need to be supported by robust and insightful information on their biological effects. The use of in vitro, ex vivo, and in vivo models is crucial to demonstrate functionalities in specific targets. In this regard, bioaccessibility, bioavailability, and tissue/organ distribution need to be fully understood and established. In addition, the structure–function relationships, concerning both descriptive and mechanistic information, between specific compounds and therapeutic objectives, need to be supported by results obtained from in vivo studies. Nevertheless, these studies are not always possible or have some limitations, particularly concerning the mechanistic information explaining the health benefits provided that should be covered with complementary experimental models. Based on these premises, this review aims to overview the contribution of the separate experimental approaches to gain insights into the bioaccessibility, bioavailability, and bioactivity of (poly)phenols. To achieve this objective, recent evidence available on the linkage of healthy/functional foods with the incidence of non‐communicable pathologies is presented. The different experimental approaches provide complementary information that allows advances to be applied to the knowledge gained on the functional properties and mechanistic facts responsible for the health attributions of polyphenols. © 2022 The Authors. Journal of The Science of Food and Agriculture published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.

show abstract

“…CVDs are a group of disorders that include the heart, blood vessels (arteries, capillaries, and veins), or both [7]. The most common CVDs that are also important for public health are ischemic heart disease, coronary heart disease, and vascular strokes.…”

Section: Introductionmentioning

confidence: 99%

Blood Flow Restriction Training in Cardiovascular Disease Patients

Angelopoulos¹,

Mylonas²,

Tsigkas³

et al. 2021

Contemporary Advances in Sports Science

View full text Add to dashboard Cite

Over the past two decades, blood flow restriction training (BFRT) has gained popularity not only in athletic performance training, but also with many researchers and physical therapists as an innovative rehabilitation tool. Blood flow restriction (BFR) exercise is a novel exercise modality in clinical settings, which induces muscle hypertrophy and increases strength with low to moderate training intensity through increased anabolic processes mediated by BFR (usually with cuff inflation). BFR limits arterial and venous blood flow and leads to blood pooling, which could increase the effects of exercise-induced training. Strength training at lower intensities (20–40% of maximum strength) in combination with BFR showed similar effects on muscle hypertrophy as training at 70% strength level without BFR. In this context, considering that periods of immobilization (or reduced functionality) due to pathology, injury, or surgery cause harmful effects on muscle mass and strength in both young and old people, muscular adaptations of occlusion exercise could be beneficial to the elderly and post-operative patients in rehabilitation regarding muscle regeneration. Furthermore, as this type of exercise does not require high loads, it might be a feasible method in cardiac rehabilitation. Therefore, this chapter aims to review all recent literature regarding the impact of low-load BFR resistance training in patients with cardiovascular pathologies on muscle strength and hypertrophy, vascular function, safety, cardiovascular responses, and inflammatory markers.

show abstract

Cardiovascular Disease: An Introduction

Cited by 35 publications

References 170 publications

Precision and Advanced Nano-Phytopharmaceuticals for Therapeutic Applications

Precision and Advanced Nano-Phytopharmaceuticals for Therapeutic Applications

Contribution of the diverse experimental models to unravelling the biological scope of dietary (poly)phenols

Blood Flow Restriction Training in Cardiovascular Disease Patients

Contact Info

Product

Resources

About